Trial
NCT05935085
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AnaptysBio, Inc.
Collaborators
—
Condition
Atopic Dermatitis Eczema
Intervention
ANB032
Why stopped
ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-14